TTX MC 138
Alternative Names: TTX-MC-138Latest Information Update: 30 Sep 2026
At a glance
- Originator TransCode Therapeutics
- Class Antineoplastics; Antisense oligonucleotides; Immunotherapies
- Mechanism of Action Cell death stimulants; Gene silencing; MicroRNA inhibitors
-
Orphan Drug Status
Yes - Pancreatic cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- Phase I/II Solid tumours
- Preclinical Glioblastoma; Osteosarcoma; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer; Unspecified
Most Recent Events
- 28 Sep 2026 Efficacy, adverse events and pharmacodynamics data from a phase I/II trial in Solid tumours released by TransCode Therapeutics
- 22 Sep 2026 TransCode Therapeutics has patent protection for TTXMC 138 in Australia
- 31 Aug 2026 Pharmacodynamics, Pharmacokinetics and adverse event data from a preclinical study in Bone cancer released by TransCode Therapeutics